

**RECORDATI: 2021 CORPORATE EVENTS' CALENDAR**

Milan, 30<sup>th</sup> November 2020 – Recordati S.p.A. hereby communicates the calendar of corporate events for 2021:

<b>22<sup>nd</sup> February</b>	Board of Directors' meeting to approve the 2020 preliminary consolidated results.
<b>18<sup>th</sup> March</b>	Board of Directors' meeting to approve the 2020 consolidated financial statements and the draft of Recordati S.p.A.'s 2020 financial statements as well as the 2020 consolidated non-financial statement.
<b>20<sup>th</sup> April</b>	Annual Shareholders' Meeting to approve Recordati S.p.A.'s 2020 financial statements.
<b>6<sup>th</sup> May</b>	Board of Directors' meeting to approve the 2021 first quarter results.
<b>29<sup>th</sup> July</b>	Board of Directors' meeting to approve the 2021 half-yearly report.
<b>28<sup>th</sup> October</b>	Board of Directors' meeting to approve the 2021 first nine months' results.

Recordati S.p.A. announces that the payment of the balance of the 2020 financial year dividend is planned for May 2021, while payment of the interim dividend for the 2021 financial year is planned for November 2021.

Information on payment date, ex-dividend date and record date will be provided after the disclosure of the 2021 trading Calendar of Borsa Italiana.

Recordati S.p.A. specifies that this press release is not a prevision of the existence of the conditions for the dividend distribution as per the above.

Any amendments to the above calendar will be promptly notified to the market.

*Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.*

*For further information:*

*Recordati website: [www.recordati.com](http://www.recordati.com)*

*Investor Relations*

*Media Relations*

**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Sede Legale  
VIA M. CIVITALI, 1  
20148 MILANO, ITALIA  
TEL. (39) 0248787.1  
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 i.v.  
REG. IMP. MILANO, MONZA, BRIANZA e LODI 00748210150  
CODICE FISCALE/P. IVA 00748210150  
R.E.A. MILANO 401832

Società Soggetta all'attività di Direzione e Coordinamento di Rossini Luxembourg S.à.r.l



RECORDATI

Marianne Tatschke  
(39)0248787393  
e-mail: investorelations@recordati.it

Studio Noris Morano  
(39)0276004736, (39)0276004745  
e-mail: norismorano@studionorismorano.com

*Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.*